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Immunostaining in Mohs Micrographic Surgery: A Review
ABDEL KADER EL TAL, MD, AYAD E. ABROU, MD,y MARK A. STIFF, MD,z AND
DAVID A. MEHREGAN, MDy
BACKGROUND With the advent of incorporating the immunoperoxidase staining technique into the
processing of frozen tissue, the use of Mohs micrographic surgery (MMS) has been expanded to include
several high-risk tumors such as lentigo maligna, malignant melanoma, and dermatofibrosarcoma pro-
tuberans.
OBJECTIVES To thoroughly review the English medical literature pertaining to the use of immunohis-
tochemical staining techniques on frozen sections during MMS and to summarize the basic relevant
outcomes from the different relevant studies.
MATERIALS AND METHODS Medline search was conducted, with the following words used in the
search criteria: ‘‘Mohs surgery,’’ ‘‘staining,’’ ‘‘immunostaining,’’ and ‘‘immunoperoxidase.’’
RESULTS Generally, all immunostains showed advantage over the traditional hematoxylin and eosin
approach. Studies of MART-1 in melanoma chemosurgery indicated that it is typically crisp and has less
background staining than MEL-5 and better staining consistency than HMB-45. In cases of desmoplastic
melanomas, S100 is the stain of choice.
CONCLUSION Immunostaining offers an advantage in MMS. Large, randomized, prospective studies
comparing the different immunostains are still lacking in the literature.
The authors have indicated no significant interest with commercial supporters.
Mohs micrographic surgery (MMS) is histori-cally used for the treatment of basal cell
carcinoma (BCC) and squamous cell carcinoma
(SCC). It has been occasionally used for the treat-
ment of other types of tumors such as malignant
melanoma1 and microcystic adnexal carcinoma,2 as
well as other malignant eccrine neoplasms,3 malig-
nant follicular tumors,4 Merkel cell carcinoma,5
sebaceous carcinoma,6 atypical fibroxanthoma,7
malignant fibrous histiocytoma,8 dermatofibrosar-
coma protuberans,9 leiomyosarcoma,10 and extra-
mammary Paget’s disease.11
Immunoperoxidase technique, using formalin-fixed
and paraffin-embedded tissue, normally takes several
hours to process. The technique works well for
regular excisions when the specimen can be pro-
cessed in 24 hours but is not suitable for Mohs sur-
gery, when tissue is regularly processed using the
frozen section technique. Initially, the Mohs tech-
nique was modified to include ‘‘rush’’ permanent
sections, particularly in instances in which
frozen section reading was difficult to interpret, as in
cases of lentigo maligna12 or lentigo maligna
melanoma.13 Subsequently, the immunohistochemi-
cal staining technique was modified to allow for
rapid staining and hence was performed on frozen
tissue in Mohs surgery.14–16 One advantage of
immunostaining frozen sections rather than
formalin-embedded sections is the prevention of loss
of antigens. In formalin-fixed tissue, the cell
membrane is generally disrupted as a result of
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autolysis, and cell-surface antigen staining is
not reliable In contrast, with frozen section staining,
cytoplasmic and cell membrane antigen-staining can
be displayed.17
Although previous techniques of immunostaining
required immunofluorescence, necessitating the use
of a specialized microscope, the current immuno-
histochemical staining techniques allow for examin-
ation of the slide under standard light microscopy.
The Immunohistochemical Staining Technique
The original, or direct, method of immunostaining
allowed a single antibody, which is conjugated to an
enzyme, to interact with an antigen present on the
cell of interest. A substrate is then added, and after a
reaction mediated by the conjugated enzyme, the
substrate will fluoresce or form an insoluble color
product deposited near the antibody (Figure 1). The
pitfall of this technique is that it requires high con-
centrations of the antibody to obtain the staining.18
In other words, the technique has low sensitivity.
The indirect, or amplifying, technique has proven to
be more efficient than the direct technique, partic-
ularly in the setting of frozen section tissue examin-
ation. In this method, the tissue is initially incubated
with a primary antibody and then washed and in-
cubated with a secondary antibody. The secondary
antibody is commonly peroxidase labeled. A chro-
mogen is added afterwards and, in the presence of
the peroxidase-labeled antibody, will form an
insoluble colored product18 (Figure 2). Commonly
used chromogens include 30-diaminobenzidine tet-
rachloride, forming a brown product, or 3-amino-
9-ethylcarbazole, forming a red product. The
advantage of this technique is the requirement for a
lower antibody concentration to detect the antigen on
formalin sections, but to shorten the time required
for processing of frozen sections to 30 to 90 minutes,
it is necessary to increase the concentration of the
antibody. Although this enhances the sensitivity
of the technique, it compromises its specificity by
increasing background nonspecific staining. Hence,
the use of negative controls in these instances is
typically advised.
Other methods of enhancing the sensitivity of the
direct and indirect techniques are antigen retrieval
and microwave heating in combination with heavy
metal–containing solutions or citrate buffers.18 Fix-
ation of the tissue affects many antigens, and fixed
tissue may not stain with the most sensitive tech-
niques. These modifications allow for better stain-
ing, or greater sensitivity, but again at the expense of
specificity and an increase in background staining.






Figure 1. Direct conjugate method. The enzyme, peroxidase
(Px) in this example, is attached directly to the antibody that







Figure 2. Indirect conjugate or sandwich method. The per-
oxidase (Px) is attached to the secondary antibody that is
specific to the primary antibody.
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The steps for the indirect technique are as follows:
(1) Cut frozen section 4 to 6mm thick
(2) Fix specimen in acetone
(3) Air dry or heat
(4) Rehydrate with Tris buffered saline (TBS)
(5) Apply antibody
(6) Rinse with TBS
(7) Apply linking agent
(8) Rinse with TBS
(9) Apply labeling agent
(10) Rinse with TBS
(11) Apply chromogen
(12) Rinse, dehydrate, clear, and mount
Some authors have demonstrated an enhance-
ment in the technique by combining some steps or
shortening the length of each step.
Methods of Review
A review of the English literature pertaining to
immunohistochemical staining technique use in
Mohs surgery was done using a Medline search. The
following words were used in the search criteria:
‘‘Mohs surgery,’’ ‘‘staining,’’ ‘‘immunostaining,’’ and
‘‘immunoperoxidase.’’ Articles relevant to the use of
immunohistochemical staining for frozen sections in
Mohs surgery of malignant skin cancers were
retrieved (Tables 1–3).
Lentigo Maligna and Malignant Melanoma
The use of MMS for treatment of lentigo maligna
and malignant melanoma has historically been
somewhat controversial. These disorders can be
difficult to diagnose under light microscopy, partic-
ularly when it comes to differentiating atypical
melanocytic proliferation from melanoma.19,20
Upon comparing hematoxylin and eosin (H&E)-
stained frozen sections to permanent sections in
melanoma, Cohen and colleagues found a sensitivity
of 73% and a specificity of 68%.21 In contrast, other
authors have reported that the sensitivity and spec-
ificity of H&E-stained frozen sections for the eval-
uation of surgical margins of lentigo maligna are
100% and 90%, respectively.22 These results can be
achieved only using excellent-quality sections and
experienced reviewers, yielding more than a 90%
survival rate at 5 years of follow-up.23
The introduction of immunostaining has signifi-
cantly decreased the controversy surrounding the use
of Mohs surgery for lentigo maligna and malignant
melanoma. It has greatly facilitated the detection
of melanocytes and the diagnosis of melanoma
on permanent sections and can be used on frozen
sections as well (Table 1).24
According to Gross and colleagues,25 to make MMS
successful for melanoma, the following four criteria
must be met: the tumor cells must be visually
identifiable in the sections, the tumor must be con-
tiguous to avoid false-negative margins, the mapping
and staining component must be technically
feasible, and the total tissue processing time should
be short enough to allow for a staged excision and
repair on the same day.
Several types of immunostains have been used to
identify abnormal melanocytes.
Human melanoma, black-45 (HMB-45) is a mouse
monoclonal antibody that recognizes a 30- to 35-
kDa melanosome-associated sialated glycoprotein.26
It is present in stage I and II melanosomes of neo-
plastic melanocytes and stage II and III melanosomes
of fetuses and infants.26,27 Staining is cytoplasmic
and granular and is independent of tyrosinase
activity.27 The sensitivity of HMB-45 for me-
lanocytes in melanoma on paraffin-embedded
sections has been reported to be 86% to 97%.28
HMB-45 staining is often negative in spindle cell
melanomas, including desmoplastic and neurotropic
melanomas, although newer antigen retrieval tech-
niques have been reported to increase sensitivity to
75% in spindle cell melanomas.29
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MEL-5 is a mouse monoclonal antibody that
recognizes gp75, the most abundant glycoprotein in
melanocytes. It is a member of the tyrosinase-related
family of proteins (TRP-1) and is an integral mem-
brane protein of melanosomes, present primarily in
stage III and IV melanosomes.30–32 Also designated
TA99, MEL-5 stains melanosome-containing cells,
including normal epidermal melanocytes, epidermal
components of benign nevi, and 95% of melanomas.
However, it also stains epithelial cells in the basal
layer of the epidermis through transfer of melano-
somes.30–33 MEL-5 may be negative in amelanotic
or desmoplastic melanoma and in the dermal
component of melanoma.31,32
The Melan-A antigen, or melanoma antigen
recognized by T cells (MART-1), is a melanocyte
differentiation antigen like gp100 and gp75 (recog-
nized by HMB-45 and MEL-5, respectively) and
tyrosinase.34,35 It is a 22-kDa cytoplasmic melano-
some-associated glycoprotein recognized by murine
monoclonal antibodies A-103 and M2-7C10. It is
present in 80% to 100% of melanomas, resting
adult melanocytes, and nevus cells in epidermal and
dermal compartments.34–39 Although one study
found a slightly higher sensitivity of HMB-45 for
melanoma than Melan-A,40 most have noted the
reverse. Blessing and colleagues41 found a 97%
positivity for Melan-A and 90% positivity for HMB-
45 in primary melanomas. In metastatic melanomas,
Melan-A stains 81% to 89% of tumors, and
HMB-45 stains 75% to 76%.35,42
S100 is a 21-Kd protein and was originally given its
name because of its solubility in 100% saturated
ammonium sulfate solution. It was first found to
stain human melanoma cells in 1981. Its function is
nor completely understood, but it is thought to
function with intracellular calcium trafficking,
microtubular assay, or both. Its specificity is low
because antibody to S100 stains Schwannomas,
ependymomas, astrogliomas, and almost all benign
and malignant melanocytic lesions and their
metastases. S100 protein is also expressed in the
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in skin and interdigitating reticulum cells in the
paracortex of lymph nodes.43
Griego and Zitelli reported a case of MMS using
HMB-45 for a recurrent acral melanoma.44 The
authors noted that HMB-45 stained portions of the
margins that were clear in frozen and permanent
sections. The patient was followed up for 22 months
with no recurrence seen.
Menaker and colleagues described a 90-minute pro-
tocol for HMB-45 staining on frozen section, com-
paring it to similar staining on permanent sections.45
Twenty patients underwent MMS with HMB-45
staining. Eleven patients were positive. One patient
had a false positive result on the HMB-45. Accord-
ingly, the HMB-45 performance on frozen sections,
in comparison with permanent sections, had a sen-
sitivity of 100% and a specificity of 95%. The au-
thors acknowledge that the specificity was decreased
because of staining of non-malignant melanocytic
neoplasms.
Zalla and colleagues described a 90-minute protocol
for HMB-45, MEL-5, Melan-A, and S100 stains.46
They performed immunostaining on 68 tumors (46
melanomas in situ and 22 invasive melanomas). In
their study, sections were stained with H&E together
with one or more immunostains to compare stain
quality and results. HMB-45, MEL-5, and Melan-A
all exhibited areas of crisp positive staining in areas
involved by tumor. When equivocal areas were noted
with one immunostain, another immunostain was
performed, or the area was considered positive, and
further layers were taken. In this study, HMB-45 was
positive in 50 of 59 tumors (85%). It was negative in
two desmoplastic neurotropic melanomas. The two
tumors were detected using immunostaining and not
on H&E-stained frozen sections. MEL-5 was per-
formed on 13 cases and stained positive 12 of the 13
tumors (92% of cases), including six of seven
HMB-45-negative tumors. One desmoplastic
neurotropic melanoma stained negative with
MEL-5. MEL-5 was found to be better than S100 in
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staining, although the authors concur with another
study, in which it was found to be less specific than
HMB-45, staining non-melanocytic lesions such as
pigmented actinic keratoses, pigmented Bowen’s
disease, and lichen planus-like keratoses.32 Melan-A
was performed on 27 cases, 26 of which were pos-
itive, including one case that was negative according
to HMB-45. One desmoplastic neurotropic
melanoma was weakly positive, and another was
negative with this stain.
Gross and colleagues performed MMS on two cases
of lentigo maligna using MEL-5.25 A 75-minute
protocol was followed. Positive controls were taken
from the center of the tumors, and negative controls
were taken from the contralateral sites. In the au-
thors’ opinion, MEL-5 was superior to the other
immunohistochemical stains because it reliably
stained epidermal melanocytes and melanoma cells.
Follow-ups of 15 and 16 months revealed no
recurrence of tumor.
Bhardwaj and colleagues47 studied the use of MEL-5
on 200 cases of primary or recurrent lentigo maligna
and malignant melanoma. MEL-5 was done in
parallel with H&E staining. The MEL-5 staining
technique required approximately 40 minutes, but
with the use of an autostainer, the time needed was
shortened to 20 minutes. There was no mention of
MEL-5 highlighting areas not previously highlighted
with H&E staining. Of the 200 patients, three
needed postoperative radiation therapy. Only one
recurrence has been observed. The mean duration of
follow-up in this study was 38.4 months. there was
no mention of the sensitivity or the specificity of the
200 tumors studied although the authors mention a
previous retrospective study that used MMS for the
treatment of melanoma in situ. In that study, the
sensitivity and specificity were 59% and 81%, re-
spectively, when comparing Mel-5-stained frozen
sections with Mel-5-stained paraffin sections.
In 2002, Kelley and Starkus reported a series of
seven patients with lentigo maligna on whom MMS
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H&E and MART-1 were compared with permanent
sections.48 MART-1 staining on frozen sections
correlated 100% with MART-1 on permanent
sections and detected the atypical melanocytes in all
seven cases. In this study, the authors emphasized the
difficulty in discerning atypical melanocytes of
lentigo maligna from the surrounding atypical
melanocytic hyperplasia of sun exposure. For that
purpose, sections from nine cases of normal photo-
damaged skin and five photoprotected cases were
evaluated and used as a baseline for comparison. The
authors concluded that, when the margin of lentigo
maligna is evaluated, confluence of atypical me-
lanocytes alone is not enough to label margins as
positive. At minimum, there must be crowding of the
atypical melanocytes.
In the same year, Albertini and colleagues reported
their experience comparing MART-1, HMB-45, and
S100.49 Their protocol required approximately 2
hours for the immunostaining to be completed. Some
patients needed more than 1 day to achieve negative
margins. Ten cases were stained with H&E and
the three mentioned stains. Positive and negative
control stains were processed for each immunostain
for each layer. MART-1 had better sensitivity than
HMB-45 and S100 and was the preferred stain in the
final pathologic determination. HMB-45 failed to
demonstrate many foci of melanocytic proliferation
visible with MART-1. S100 had poor controls on
frozen sections, although good controls were
achieved when permanent fixation was used.
In 2004, Bricca and colleagues suggested a shorter
protocol for Melan-A staining.50 In brief, the pro-
tocol decreased the duration from a 90-minute to a
60-minute protocol. In comparison with other pro-
tocols, the 1-hour protocol eliminated the linking
step and shortened the protein blocking step. The
protein blocking step was reduced by using a
blocking agent that has high quantities of nonspe-
cific immunoglobulin (Ig)G. The linking step was
omitted by using a special secondary antibody that is
bound to a spherical polymer that is directly at-
tached to horseradish peroxidase (HRP). In this
study, 40 patients with lentigo maligna and malig-
nant melanoma were evaluated. The MART-1 stain
delineated the malignant cells in three equivocal
cases and one negative case according to H&E
staining.
In 2008, Kimyai-Asadi and colleagues51 reported a
protocol for rapid MART-1 staining that needed
only 20 minutes to perform. The heating period,
fixation phase, drying phase, rehydration phase,
blocking phase, antibody application phase, buffer-
ing phases, HRP application phase, and mounting
phase were shorter in the 20-minute protocol than in
the 1-hour protocol by Bricca and colleagues.
MART-1 was able to delineate all 30 malignant
melanomas studied, although there was no follow-
up on the patients. The authors mention that MART-
1 enhances the sensitivity and specificity of mela-
noma detection on frozen section, although it is not a
reliable stain for spindle cell melanoma.
Melan-A epidermal staining on frozen section is in-
tense and crisp, with regular staining of normal basilar
cells and less background staining than MEL-5, thus
giving less equivocal results than MEL-5. The consis-
tency of Melan-A stain is better than that of HMB-45,
and more cases are detected than with HMB-45.46,49
However, in the case of desmoplastic melanomas,
S100 offers advantages over the other stains.
BCC and SCC
Although the histologic recognition of BCC and SCC
in frozen sections is straightforward in most cases,
situations exist in which clear delineation and map-
ping of the tumor infiltration can be difficult. For
example, the presence of a dense inflammatory
lymphocytic infiltrate in tissue sections may make it
difficult, if not impossible, to detect the malignant
cells.
Cytokeratins are one of the five types of intermediate
filaments that constitute the cytoskeleton of the cell.
At least 20 types of cytokeratins have been charac-
terized. Glandular epithelium is composed mainly of
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low- (LMW) to intermediate-molecular-weight
keratins, and squamous epithelium consists primarily
of the more complex high-molecular-weight
(HMW) keratins. BCCs express cytokeratins 5, 14,
15, and 17,52–55 and cutaneous SCCs express cytok-
eratins 5, 6, 8, 14, 17, and 18.53,56 In routine practice,
a cocktail that recognizes a wide spectrum of keratins
is used. AE1 detects the HMW cyto-
keratins 10, 14, 15, and 16, and also the LMW
cytokeratin 19 (acidic keratin). AE3 detects the
HMW cytokeratins 1, 2, 3, 4, 5, and 6 and the LMW
cytokeratins 7 and 8 (basic keratin). By combining
these two reagents, a single reagent with a broad
spectrum of reactivity against HMW and LMW
cytokeratins is obtained.
In 1984, Robinson and Gottschalk57 evaluated sev-
eral tumors using cytokeratin antibodies using two
kinds of techniques: immunofluorescence and im-
munoperoxidase (Table 2). Their study indicated
that immunoperoxidase is sensitive in recognizing
BCCs, keratoacanthomas, and desmoplastic tri-
choepitheliomas. Monoclonal and polyclonal anti-
bodies were used. Although polyclonal antikeratin
antibodies stained all tumors mentioned previously,
the intensity of the staining correlated with the
degree of differentiation of the tumor. Monoclonal
antibodies, on the other hand, stained BCC cells
with varying intensity and did not stain poorly
differentiated SCC.
In 1987, Robinson used several monoclonal anti-
keratin antibody immunostains to compare invasive
BCC and SCC with their less aggressive counter-
parts.58 AE1, AE3, EKH4, Miles, and AE1-AE3
combination antibodies were used. EKH4 is a
monoclonal mouse antibody derived from human
trichilemmoma cells. Miles antibodies are derived
from bovine hoof prekeratin antibodies and will
stain the granular and corneal epidermal layers.
Nodular BCC exhibited staining with AE1, EKH4,
and an AE1-AE3 combination but not Miles anti-
bodies. As the tumor becomes more aggressive, AE1-
AE3 still stain the tumor, but EKH4 and AE1 will
stain only peripheral cells and ultimately becomes
occasional and nonreliable. Well-differentiated SCC
displayed strong staining for the Miles antibody in
keratin pearls and AE1-AE3 staining throughout the
tumor. In contrast to nodular BCC, AE1 and EKH4
only weakly and occasionally stained the malignant
cells. As the SCC became more invasive, there was
loss of the AE1-AE3 stain at the deeper margins.
In 1994, Zachary and colleagues used cytokeratin
AE1 in 20 cases of SCC.14 The immunostain de-
tected all 20 SCCs. In eight of 20 cases, small clumps
or single cells of residual tumor were identified using
cytokeratin-positive staining. The residual tumor
often resided in areas of inflammation. Positive
controls were taken from the vertical sections of the
primary tumor. In the papillary dermis, the occa-
sional presence of globular material that stained
positive with the procedure was noted and might
have beeen mistaken for a false-positive result if no
positive controls had been used.
Jimenez and colleagues16 used a broad-spectrum
anticytokeratin (AE1/AE3) together with anticyto-
keratin 14 in the detection of BCC and SCC during
MMS. They described a 1-hour protocol for the
anticytokeratin stain. In this study, the immuno-
staining technique was able to pick up one of 12
BCCs, and three of six SCCs where only dense in-
flammatory infiltrate was seen on H&E. The stain
was also able to delineate and map out more accu-
rately subtle tumor islands in eight cases of mor-
pheaform BCCs and highlighted perineural
involvement in five cases of BCC and five cases of
SCC with perineural involvement.
Immunostains other than cytokeratins have also
been used. TNKH1, an antiglycoprotein antibody, is
a monoclonal antibody that was primarily developed
in mice to recognize differentiation antigen of a hu-
man melanoma cell line (A375). It was also found to
stain epithelial tumors considered to be derived from
or differentiating toward hair follicle. In their study,
Setoyama and colleagues59 showed that TNKH1
stained 32 of 32 BCCs, labeling the tumors in their
entirety. The antibody was useful in delineating the
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upper hair follicle and eccrine duct from BCC
tumors. The antibody also irregularly stained one of
two SCCs over the periphery of the tumor.
Ber-EP4 is an antibody raised against an epitope of
the protein region of two human epithelial membrane
glycoproteins.60 Its ability to differentiate BCC from
SCC has been demonstrated previously. Kist and
colleagues61 and Jimenez and colleagues62 found Ber-
EP4 to be useful during MMS for BCC tumors.
Krunic and colleagues used the monoclonal antibody
33-3D, a mouse IgM monoclonal antibody that
recognizes the cytoplasmic domains of human
desmoglein, during MMS for 18 cases of BCC.63 The
protocol described for staining required approxi-
mately 60 minutes to perform. The antibody shows
intense pericellular staining around normal cells and
will show general or diffuse cytoplasmic staining or a
reduction in staining in areas of tumors. The anti-
body helps to differentiate BCC from hair follicles or
from folliculocentric basaloid proliferation (FBP) in
horizontal sections.63 FBP is vertically oriented
basaloid proliferations that can radiate outward and
downward from the hair follicle and up toward the
skin edges. It surrounds BCC and may extend inward
to the proliferating border of the neoplasm.64 In
another study, Krunic and colleagues stained 24
SCCs and 12 keratoacanthomas (KAs) using the
antidesmoglein antibodies on frozen sections from
excised lesions.65 All 12 KAs showed extensive,
uniform pericellular staining for desmoglein
throughout the nonkeratinized layers of the tumor,
whereas all five SCCs showed only focal pericellular
staining, and seven SCCs showed absence of
staining.
Other Kinds of Tumors
Dermatofibrosarcoma Protuberans
Dermatofibrosarcoma protuberans (DFSP) is a
tumor that is commonly removed using MMS. The
problem is that its histologic differentiation on
H&E-stained frozen sections can be difficult, par-
ticularly at the margin of the tumor and at areas of
scarring from previous surgical procedures. Tradi-
tional surgical excision usually fails to treat the
microscopic extensions, and in most series, recur-
rence rates of 49% to 53% have been reported, with
the majority developing 1 to 2 years after therapy.66
When surgical margins of 3 cm have been used, the
recurrence rate drops to 10% to 20%.8
In 1985, Robinson reported a 5-year prospective
study of four cases of DFSP treated using MMS.67
Staining with keratin, glial fibrillary acid protein,
and desmin were attempted but were negative in all
four tumors (Table 3).
CD34 antigen is typically found in hematopoietic
stem cells, endothelium, dermal and periadnexal
dendritic cells, and endoneuronal dendritic cells. Its
detection helps in differentiating DFSP from keloids,
dermatofibroma, atypical fibroxanthoma, and ma-
lignant fibrous histiocytoma. There is greater vari-
ability of CD34 staining in nodular areas than in
plaque areas of DFSP.67
In 1994, Jimenez and colleagues used CD-34
immunostaining on MMS for a DFSP over the left
medial breast of a 13-year-old girl.68 The protocol
described took approximately 1 hour. The tumor
immunostaining was strongly positive. Positive con-
trol was used from the first stage, where tumor was
present.
In 1996, Garcia and colleagues reported the use of
CD-34 immunostaining during MMS on another
patient with a DFSP over the abdomen.69 The tumor
again strongly stained with CD-34, although it was
negative on the initial biopsy. The authors recom-
mend biopsies from the plaque areas of the tumor
with the inclusion of fatty tissue to improve the
diagnostic yield of the CD-34 immunostain.
Miscellaneous Tumors
Harris and colleagues reported the treatment of
extramammary Paget’s disease on one patient using
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carcinoembryonic antigen (CEA) during MMS.15
The use of a quick-staining immunoalkaline phos-
phatase kit that, when combined with high-affinity
primary antibodies, reduced the total staining time
to 30 minutes, producing moderate-intensity cyto-
plasmic staining. As an internal control, the CEA
stains eccrine and apocrine cells uniformly through-
out the cytoplasm. Although Periodic Acid-Schiff
stain can be used during MMS for extramammary
Paget’s disease, the authors find CEA to be a superior
diagnostic method.
Smith and colleagues reported the treatment of one
case of granular cell tumor on the right plantar
foot.70 In their case report, the tumor was tracking
along the nerves, and the last three layers during the
surgery showed positivity only with S100 but not
with the H&E staining.
Albertini and colleagues have used actin stain in
addition to H&E and Masson trichrome in a case of
a tender infantile digital fibromatosis.71 Although
the tumor involved the joint capsule and was left
positive at that margin, 2-year follow-up showed no
recurrence of disease.
Marra and colleagues described a 45- to 60-minute
protocol using automated staining for LMW cyto-
keratin, pancytokeratin (AE1/AE3), CEA, epithelial
membrane antigen (EMA), and vimentin during
MMS for one case of primary cutaneous mucinous
carcinoma.72 In this report, the tumor was positive
for LMW cytokeratin, AE1/AE3, and less clearly
EMA but was negative for CEA and vimentin. The
authors commented that the adnexal structures nor-
mally stained positive with the LMW cytokeratin
and could thereby confound the interpretation of
immunostained slides, whereas the tumor cells
lacked histopathologic characteristics of acinar or
ductal elements.
Jimenez and colleagues used pan-cytokeratin stain-
ing (AE1/AE3) during MMS for lymphoepithelioma-
like carcinoma of the skin.73 The staining was
particularly helpful in some areas where the tumor
cells were difficult to delineate within the reactive
infiltrate. Normal epidermis was used as positive
internal control, and negative control runs were
performed in parallel. The patient was free of
recurrence after a follow-up of 12 months.
Allee and colleagues have used cytokeratin-17 dur-
ing MMS of a recurrent trichilemmal carcinoma over
the left cheek.74 Positive and negative margins were
taken. The tumor showed strong cytoplasmic stain-
ing of the tumor cells for cytokeratin-17 and failed to
stain for cytokeratin-15. Cytokeratin-17 is an inter-
mediate filament expressed constitutively in the
outer root sheath of the hair follicles but not in the
interfollicular epidermis, whereas cytokeratin-15
is expressed in a subpopulation of keratinocytes in
the bulge area of the outer root sheath.
Hardaway and colleagues75 have used HMB-45,
S100, vimentin, desmin, pankeratin, 34 BE-12, Cam-
5.2, CD-68, CD34, Factor VIIIa, actin, and
MyoD1 during MMS for an embryonal
rhabdomyosarcoma of the cheek. S100, vimentin,
desmin, actin and MyoD1 were the only positive
stains. The authors emphasize that MyoD1 and
myogenin are DNA-binding proteins that are
involved in the differentiation of mesenchymal pro-
genitor cells and have been used as markers in
characterizing rhabdomyosarcoma.
Prevalence and Costs
In 2001, Robinson conducted a survey of 108 Mohs
surgery laboratories.76 Thirteen laboratories were
doing immunostaining at the time (13%). Perfor-
mance of immunostaining was associated with
resections of melanoma or DFSP, with only one
laboratroy using an automated immunostainer.
HMB-45 was used by 50% of the labs, S100 by
42%, Mart-1 and MEL-5 by 42%, antikeratin by
42%, and anti-CD34 by 33%. The author empha-
sized that, by using polyclonal antibodies instead of
monoclonal antibodies and by using higher antibody
titers, the processing time would be further short-
ened and would fall within the expectations of Mohs
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surgeons. The International Classification of
Diseases, Ninth Revision, code for immunostaining
sections in Mohs surgery is 88,342, with a current
Medicare reimbursement of approximately $100.
The current estimate of cost per slide is between $20
and $25.
Conclusion
The use of immunohistochemical staining during
MMS is definitely on the rise, particularly in cases of
lentigo maligna and malignant melanoma, but large
randomized prospective studies comparing the
different immunostains are lacking in the literature.
As a result of increasing familiarity with the stains,
faster processing, and lowering costs of the anti-
bodies, Mohs surgeons should be encouraged to
integrate immunostaining into their laboratory
routine.
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